research use only

Remdesivir (GS-5734) Antiviral Agent

Name: Remdesivir (GS-5734)
Brand: Selleck Chemicals
SKU: S8932
Availability: InStock
Rating: 5 (98 reviews)

Cat.No.S8932

Remdesivir (GS-5734) is a monophosphoramidate prodrug of an adenosine analog and an investigational broad-spectrum antiviral agent with in vitro activity against multiple RNA viruses, including Ebola and CoV.

Chemical Structure

Molecular Weight: 602.58

Jump to Mechanism of Action Cell Culture & Working Concentration Solubility Chemical Information, Storage & Stability

Quality Control

Batch: Purity: 99.94%

99.94

Related Targets	Bacterial Antibiotics Anti-infection Fungal COVID-19 Parasite Reverse Transcriptase HIV HCV Protease SARS-CoV HIV Protease Influenza Virus β-lactamase Integrase HBV CMV Neuraminidase HCV HSV RSV Enterovirus Thioredoxin Reductase 3C-Like Protease Ribosomal Peptidyl Transferase HPV
Related Products	Moroxydine HCl Aloperine GS-441524 Oleanolic Acid NGI-1 Lapachol Saikosaponin B2 Harringtonine U18666A Carrageenan Goitrin (+)-JNJ-A07 Lanatoside C Aloin B Dehydroandrographolide Succinate LL-37 acetate Saikosaponin C CBS1117 Glyceryl monocaprate (Monocaprin) DTNB Honeysuckle flower Extract Riamilovir Isoprinosine Phosphonoacetic acid Norwogonin Epigoitrin Geranium wilfordii Extract BVDV IN-1 Theaflavin 3,3'-digallate Qstatin

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
Hep2	Antiviral activity assay	4 days	EC50 = 0.015 μM	28124907
TERT-immortalized HMVEC	Antiviral activity assay	3 to 4 days	EC50 = 0.053 μM	28124907
HuH7	Antiviral activity assay	3 days	EC50 = 0.057 μM	28124907
HuH7	Antiviral activity assay	3 days	EC50 = 0.07 μM	28792763
macrophages	Antiviral activity assay	48 h	EC50 = 0.086 μM	28124907
macrophages	Antiviral activity assay	48 h	EC50 = 0.086 μM	28792763
HeLa	Antiviral activity assay	48 h	EC50 = 0.1 μM	28124907
HeLa	Antiviral activity assay	48 h	EC50 = 0.14 μM	28792763
MT4	Cytotoxicity assay	4 to 5 days	CC50 = 1.7 μM	28124907
Hep2	Cytotoxicity assay	4 to 5 days	CC50 = 6.1 μM	28124907
HuH7	Cytotoxicity assay	3 days	CC50 = 36 μM	28124907
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight	602.58	Formula	C₂₇H₃₅N₆O₈P	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1809249-37-3	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	CCC(CC)COC(=O)C(C)NP(=O)(OCC1C(C(C(O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (165.95 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 16 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (8.30mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro	Remdesivir (GS-5734) exhibits antiviral activity against multiple variants of EBOV in cell-based assays (EC50=0.06-0.14 μM) and broad-spectrum antiviral activity in vitro against other pathogenic RNA viruses. ^[1] This compound acts as a broad-spectrum therapeutic to protect against CoVs with EC50 of 0.03 μM for murine hepatitis virus in delayed brain tumor cells and 0.074 μM for SARS-CoV and MERS-CoV in HAE cells.^[2]
In vivo	Regardless of the time of initiation, treatment with Remdesivir (GS-5734) at 3 mg/kg confers improved survival. All animals in which a 10 mg/kg regimen is initiated 3 days after virus exposure survive to the end of the in-life phase. However, the antiviral effects are consistently greater in animals administered repeated 10 mg/kg doses. The 10 mg/kg D3 (administered beginning 3 days after virus exposure) regimen is associated with amelioration of EVD-related clinical disease signs and markers of coagulopathy and end organ pathophysiology.^[1]
References	[1] https://pubmed.ncbi.nlm.nih.gov/26934220/ [2] https://pubmed.ncbi.nlm.nih.gov/29511076/

Applications

Methods	Biomarkers	PMID
Western blot	delayed chain termination of RNA synthesis tGFP-BlaR / Actin ACE2 / Actin VP0 / VP2	30987343
Growth inhibition assay	Cell viability Cell viability Cell viability	33835389
Pharmacokinetics	plasma concentration plasma concentration	32589775
Immunofluorescence	MERS-CoV S Protein viral S protein and E-caherin SARS-CoV-2 / E‐cadherin / VE‐cadherin SARS-CoV-2 viral dsRNA replication intermediates	33376043
Viral loads and virus titers	SARS-CoV-2	32516797

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):